Journal article
Anti-angiogenesis in Personalized Therapy of Lung Cancer
Abstract
Upregulation of angiogenesis is a frequent occurrence in lung cancer and is reported to represent a negative prognostic factor. This provides a rationale for the development and evaluation of anti-angiogenic agents. To date bevacizumab, a monoclonal antibody directed against serum VEGF, is the only anti-angiogenic agent that has demonstrated improved overall survival for patients with lung cancer. Meta-analysis of trials of bevacizumab in …
Authors
Ellis PM
Journal
Advances in Experimental Medicine and Biology, Vol. 893, , pp. 91–126
Publisher
Springer Nature
Publication Date
2016
DOI
10.1007/978-3-319-24223-1_5
ISSN
0065-2598